User login
Clinical Takeaways in Thrombocytopenia From ASH 2023
The clinical takeaways in immune thrombocytopenia (ITP) from the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition include the relative merits of advanced therapies, efficacy of novel therapies, and infection risk for patients with chronic ITP.
Dr Howard Liebman, of the Keck School of Medicine in Los Angeles, California, opens with a database analysis of patients with primary ITP who were first-time users of advanced therapies, such as rituximab and thrombopoietin (TPO) receptor agonists. The analysis found that despite their relative merits, all the drugs carried a significant risk for adverse events.
Next, he reports on a study examining whether newly diagnosed patients or patients with chronic ITP had better results from the use of avatrombopag, a TPO receptor agonist. Reassuringly, there were no differences in outcomes.
Dr Liebman then discusses the updated results of an ongoing study of rilzabrutinib, a Bruton kinase inhibitor. This analysis showed that the drug achieved rapid, stable, and durable platelet responses.
He next turns to a Danish registry study on infection in patients with chronic ITP, which revealed an ongoing, cumulative risk for infection over 10 years.
Finally, Dr Liebman reports on a study that showed women who develop ITP during pregnancy require more interventions than do women with chronic ITP who become pregnant, and many develop chronic disease after delivery.
--
Howard A. Liebman, MD, Professor of Medicine and Pathology, University of Southern California, Keck School of Medicine; Attending Physician, Department of Medicine, Hematology, Norris Comprehensive Cancer Center, Keck Medicine at University of Southern California, Los Angeles, California
Howard A. Liebman, MD, has disclosed the following relevant financial relationships:
Serve(d) as a consultant for: Novartis; Sanofi; Sobi
Received research grant from: Janssen Pharmaceuticals; Sanofi
The clinical takeaways in immune thrombocytopenia (ITP) from the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition include the relative merits of advanced therapies, efficacy of novel therapies, and infection risk for patients with chronic ITP.
Dr Howard Liebman, of the Keck School of Medicine in Los Angeles, California, opens with a database analysis of patients with primary ITP who were first-time users of advanced therapies, such as rituximab and thrombopoietin (TPO) receptor agonists. The analysis found that despite their relative merits, all the drugs carried a significant risk for adverse events.
Next, he reports on a study examining whether newly diagnosed patients or patients with chronic ITP had better results from the use of avatrombopag, a TPO receptor agonist. Reassuringly, there were no differences in outcomes.
Dr Liebman then discusses the updated results of an ongoing study of rilzabrutinib, a Bruton kinase inhibitor. This analysis showed that the drug achieved rapid, stable, and durable platelet responses.
He next turns to a Danish registry study on infection in patients with chronic ITP, which revealed an ongoing, cumulative risk for infection over 10 years.
Finally, Dr Liebman reports on a study that showed women who develop ITP during pregnancy require more interventions than do women with chronic ITP who become pregnant, and many develop chronic disease after delivery.
--
Howard A. Liebman, MD, Professor of Medicine and Pathology, University of Southern California, Keck School of Medicine; Attending Physician, Department of Medicine, Hematology, Norris Comprehensive Cancer Center, Keck Medicine at University of Southern California, Los Angeles, California
Howard A. Liebman, MD, has disclosed the following relevant financial relationships:
Serve(d) as a consultant for: Novartis; Sanofi; Sobi
Received research grant from: Janssen Pharmaceuticals; Sanofi
The clinical takeaways in immune thrombocytopenia (ITP) from the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition include the relative merits of advanced therapies, efficacy of novel therapies, and infection risk for patients with chronic ITP.
Dr Howard Liebman, of the Keck School of Medicine in Los Angeles, California, opens with a database analysis of patients with primary ITP who were first-time users of advanced therapies, such as rituximab and thrombopoietin (TPO) receptor agonists. The analysis found that despite their relative merits, all the drugs carried a significant risk for adverse events.
Next, he reports on a study examining whether newly diagnosed patients or patients with chronic ITP had better results from the use of avatrombopag, a TPO receptor agonist. Reassuringly, there were no differences in outcomes.
Dr Liebman then discusses the updated results of an ongoing study of rilzabrutinib, a Bruton kinase inhibitor. This analysis showed that the drug achieved rapid, stable, and durable platelet responses.
He next turns to a Danish registry study on infection in patients with chronic ITP, which revealed an ongoing, cumulative risk for infection over 10 years.
Finally, Dr Liebman reports on a study that showed women who develop ITP during pregnancy require more interventions than do women with chronic ITP who become pregnant, and many develop chronic disease after delivery.
--
Howard A. Liebman, MD, Professor of Medicine and Pathology, University of Southern California, Keck School of Medicine; Attending Physician, Department of Medicine, Hematology, Norris Comprehensive Cancer Center, Keck Medicine at University of Southern California, Los Angeles, California
Howard A. Liebman, MD, has disclosed the following relevant financial relationships:
Serve(d) as a consultant for: Novartis; Sanofi; Sobi
Received research grant from: Janssen Pharmaceuticals; Sanofi
